Adaptive CEO Chad Robins presenting at Life Science Innovation Northwest Conference on July 11
SEATTLE, WA, June 10, 2012 – Chad Robins, co-Founder and CEO of Adaptive Biotechnologies, will speak at the Life Science Innovation Northwest 2012 conference on Wednesday, July 11. The conference is being held at the Washington State Convention Center in Seattle, WA. Mr. Robins is scheduled to speak at 2:10 PM.
Also speaking at the conference will be Jeff Raikes, CEO, Bill & Melinda Gates Foundation, and G. Steven Burrill, CEO, Burrill & Company.
About Adaptive Biotechnologies Corporation and immunoSEQ™
Adaptive Biotechnologies Corporation (http://www.adaptivebiotech.com), headquartered in Seattle, WA, is pioneering the field of genomic immunology. The company’s core competency is developing next generation sequencing assays that characterize the adaptive immune system, serving as a platform technology to the research community and the biopharmaceutical industry. Its flagship commercial product, immunoSEQ (http://www.immunoSEQ.com), uses a proprietary immune profiling assay to analyze T cells and B cells – critical components of the adaptive immune system’s defense against disease – with unprecedented depth and specificity. Sequencing the variable region of these immune cells allows researchers to characterize the complete immune repertoire of a patient or group of patients in search of immunologic biomarkers. Fueled by discoveries from immunoSEQ, the company is currently developing a pipeline of clinical assays that are specific to cancer diagnosis and prognosis. All of Adaptive Biotechnologies’ assays are coupled with a cloud-computing infrastructure that simplifies the interpretation of massive quantities of data in a user-friendly interface. immunoSEQ was launched in September 2010 and has a worldwide customer base.